Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 1, 2010, Pages 48-54

  Zhao, Gang ^a   Zhao, Hong ^a   Tu, Ling ^a   Xu, Xizhen ^a   Zheng, Changlong ^a   Jiang, Meihua ^a   Wang, Peihua ^a   Wang, Daowen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

5 6 nephrectomy; Chronic tubulointerstitial fibrosis; Irbesartan; Signaling pathway

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD6 PROTEIN; SMAD6 PROTEIN, RAT; TETRAZOLE DERIVATIVE; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; FIBROSIS; KIDNEY DISEASE; MALE; METABOLISM; NEPHRECTOMY; NEPHROSCLEROSIS; PATHOLOGY; RAT; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; FIBROSIS; KIDNEY DISEASES; MALE; NEPHRECTOMY; NEPHROSCLEROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; SMAD6 PROTEIN; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77149131233     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0109-1     Document Type: Article

References (42)

1. J. Yang Y. Liu 2001 Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis Am J Pathol 159 4 1465 1475 1:STN:280:DC%2BD3Mrjs1agug%3D%3D 11583974
2. R. Hirschberg 2005 Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis J Am Soc Nephrol 16 1 9 11 10.1681/ASN. 2004110901 15574504 (Pubitemid 43073151)
3. A.A. Eddy 2000 Molecular basis of renal fibrosis Pediatr Nephrol 15 3-4 290 301 10.1007/s004670000461 1:STN:280:DC%2BD3M7lt1Olug%3D%3D 11149129
4. Y. Liu 2006 Renal fibrosis: new insights into the pathogenesis and therapeutics Kidney Int 69 2 213 217 10.1038/sj.ki.5000054 1:CAS:528: DC%2BD28XksVKqsg%3D%3D 16408108 (Pubitemid 43323069)
5. G. Carvajal J. Rodríguez-Vita R. Rodrigues-Díez, et al. 2008 Angiotensin II activates the smad pathway during epithelial mesenchymal transdifferentiation Kidney Int 74 5 585 595 10.1038/ki.2008.213 1:CAS:528:DC%2BD1cXpvVaiur4%3D 18509316
6. B.C. Liu H.L. Xia J. e. al. Wu 2007 Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction Acta Pharmacol Sin 28 11 1810 1818 10.1111/j.1745-7254.2007.00649.x 1:CAS:528:DC%2BD2sXhtlGmsLrN 17959033 (Pubitemid 350029323)
7. X. Ruan C. Wagner C. Chatziantoniou, et al. 1997 Regulation of angiotension II receptor AT1 subtypes in renal afferent rterioles during chronic changes in sodium diet J Clin Invet 9 5 1072 1081 10.1172/JCI119235
8. A. Zhou L. Yu J. Li, et al. 2000 Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor Hypertens Res 23 4 391 397 10.1291/hypres.23.391 1:CAS:528:DC%2BD3cXlsFGmu7w%3D 10912779
9. R.E. Schmieder S. Martin G.E. Lang, et al. 2009 Angiotensin blockade to reduce microvascular damage in diabetes mellitus Dtsch Arztebl Int 106 34-35 556 562 19795011
10. K.F. Croom G.L. Plosker 2008 Irbesartan: a review of its use in hypertension and diabetic nephropathy Drugs 68 11 1543 1569 10.2165/00003495- 200868110-00008 1:CAS:528:DC%2BD1cXhtVGjs7vP 18627212 (Pubitemid 352001192)
11. C. Hinojosa-Laborde B.H. Frohlich A.W. Cowley Jr 1992 Whole body autoregulation in reduced renal mass hypertension Hypertension 20 5 659 665 1:STN:280:DyaK3s%2Flt1Ohsw%3D%3D 1358822
12. J. Karalliedde G. Viberti 2006 Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes J Hum Hypertens 20 4 239 253 10.1038/sj.jhh.1001982 1:CAS:528:DC%2BD28XitlKms7g%3D 16452996
13. L. Tu X. Xu H. Wan, et al. 2008 Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats Hum Gene Ther 19 4 318 330 10.1089/hum.2007.138 1:CAS:528: DC%2BD1cXltFeisbc%3D 18402547 (Pubitemid 351591428)
14. M. Anjaneyulu K. Chopra 2004 Effect of irbesartan on the antioxidant defense system and nitric oxide release in diabetic rat kidney Am J Nephrol 24 5 488 496 10.1159/000080722 1:CAS:528:DC%2BD2cXhtVGmtrjL 15353911 (Pubitemid 39656663)
15. M. Prieto A. Rodríguez-Peña M. Arévalo, et al. 2005 Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction Kidney Blood Press Res 28 1 32 40 10.1159/000081439 1:CAS:528:DC%2BD2MXkslSn 15475654 (Pubitemid 40069635)
16. G. Wolf E. Ritz 2005 Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications Kidney Int 67 3 799 812 10.1111/j.1523-1755. 2005.00145.x 1:CAS:528:DC%2BD2MXis1Grtrc%3D 15698420 (Pubitemid 41623305)
17. S. Sekine K. Nitta K. Uchida, et al. 2003 Possible involvement of mitogen-activated protein kinase in the angiotensin II -induced fibronectin synthesis in renal interstitial fibroblasts Arch Biochem Biophys 415 1 63 68 10.1016/S0003-9861(03)00163-2 1:CAS:528:DC%2BD3sXksVakur8%3D 12801513 (Pubitemid 36687917)
18. M.F. Walsh D.R. Ampasala A.K. Rishi, et al. 2009 TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements Biochim Biophys Acta 1789 2 88 98 1:CAS:528:DC%2BD1MXntFekuw%3D%3D 19059368
19. A.R. Tan G. Alexe M. Reiss 2009 Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115 3 453 495 10.1007/s10549-008-0184-1 1:CAS:528:DC%2BD1MXmsVCrtLg%3D 18841463
20. I.M. Liu S.H. Schilling K.A. Knouse, et al. 2009 TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch EMBO J 28 2 88 98 10.1038/emboj.2008.266 1:CAS:528:DC%2BD1cXhsFWisbfL 19096363
21. J.A. Jones F.G. Spinale J.S. Ikonomidis 2009 Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis J Vasc Res 46 2 119 137 10.1159/000151766 1:CAS:528: DC%2BD1MXitVCksrc%3D 18765947
22. Y.M. Fleming G.J. Ferguson L.C. Spender, et al. 2009 TGF-beta-m-ediated activation of RhoA signaling is required for efficient (V12)HaRas and (V600E)BRAF transformation Oncogene 28 7 983 993 10.1038/onc.2008.449 1:CAS:528:DC%2BD1cXhsV2rsLvI 19079344
23. S. Zhao S. Ammanamanchi M. Brattain, et al. 2008 Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells J Biol Chem 283 17 11 293 11 301 10.1074/jbc.M800154200 1:CAS:528:DC%2BD1cXkvVSgsbs%3D
24. S. Zanotti A. Smerdel-Ramoya L. Stadmeyer, et al. 2008 Activation of the ERK pathway in osteoblastic cells, role of gremlin and BMP-2 J Cell Biochem 104 4 1421 1426 10.1002/jcb.21715 1:CAS:528:DC%2BD1cXosFyktL8%3D 18286547 (Pubitemid 351961711)
25. M.F. Walsh D.R. Ampasala J. Hatfield, et al. 2008 Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad- and p38-dependent mechanisms Am J Pathol 173 2 385 399 10.2353/ajpath.2008.070729 1:CAS:528:DC%2BD1cXhtVegtbrI 18583311
26. R. Schulz T. Vogel R. Dressel, et al. 2008 TGF-beta superfamily members, ActivinA and TGF-beta1, induce apoptosis in oligodendrocytes by different pathways Cell Tissue Res 334 3 327 338 10.1007/s00441-008-0714-5 1:CAS:528:DC%2BD1MXptFKjsw%3D%3D 19002501
27. M.F. Ramos M.W. Lamé H.J. Segall, et al. 2008 Smad signaling in the rat model of monocrotaline pulmonary hypertension Toxicol Pathol 36 2 311 320 10.1177/0192623307311402 1:CAS:528:DC%2BD1cXls1KgtLY%3D 18367643
28. H.Y. Qureshi G. Ricci M. Zafarullah 2008 Smad signaling pathway is a pivotal component of tissue inhibitor of metalloproteinases-3 regulation by transforming growth factor beta in human chondrocytes Biochim Biophys Acta 1783 9 1605 1612 10.1016/j.bbamcr.2008.04.005 1:CAS:528:DC%2BD1cXns1Snur8%3D 18471442
29. P. Owens H. Bazzi E. Engelking, et al. 2008 Smad4-dependent desmoglein-4 expression contributes to hair follicle integrity Dev Biol 322 1 156 166 10.1016/j.ydbio.2008.07.020 1:CAS:528:DC%2BD1cXhtFyls77P 18692037
30. J. Rodríguez-Vita E. Sánchez-López V. Esteban, et al. 2005 Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism Circulation 111 19 2509 2517 10.1161/01.CIR.0000165133.84978.E2 15883213 (Pubitemid 40696140)
31. M. Ruiz-Ortega M. Rupérez V. Esteban, et al. 2006 Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases Nephrol Dial Transplant 21 1 16 20 10.1093/ndt/gfi265 1:CAS:528: DC%2BD28XisFKhtQ%3D%3D 16280370 (Pubitemid 43057101)
32. B.M. Brenner M.E. Cooper D. de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 861 869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518 (Pubitemid 34940825)
33. E.J. Lewis L.G. Hunsicker W.R. Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 851 860 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D 11565517 (Pubitemid 34940824)
34. H.H. Parving H. Lehnert J. Bröchner-Mortensen, et al. 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 870 878 10.1056/NEJMoa011489 1:CAS:528:DC%2BD3MXntlelsLY%3D 11565519 (Pubitemid 34940826)
35. T.M. Seccia C. Maniero A.S. Belloni, et al. 2008 Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis J Hypertens 26 10 2022 2029 10.1097/HJH.0b013e328309f00a 1:CAS:528:DC%2BD1cXhtFCju7zL 18806627
36. R.R. Wenzel 2005 Renal protection in hypertensive patients: selection of antihypertensive therapy Drugs 65 Suppl2 S29 S39
37. S. Li B. Cao Q.H. Feng, et al. 2003 Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats Zhonghua Er Ke Za Zhi (in Chinese) 41 11 817 821
38. M.W. Taal K. Zandi-Nejad B. Weening, et al. 2000 Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney Kidney Int 58 4 1664 1676 10.1111/j.1523-1755.2000.00327.x 1:CAS:528:DC%2BD3cXntlylurs%3D 11012900
39. J.E. Toblli G. DeRosa G. Cao, et al. 2004 ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats Kidney Int 65 6 2343 2359 10.1111/j.1523-1755.2004.00661.x 1:CAS:528:DC%2BD2cXltFKgt74%3D 15149348 (Pubitemid 38670021)
40. L.J. Ma S. Jha H. Ling, et al. 2004 Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats Kidney Int 65 1 106 115 10.1111/j.1523-1755.2004.00381.x 1:CAS:528: DC%2BD2cXmt1WjsQ%3D%3D 14675041 (Pubitemid 38037495)
41. H. Yokoi A. Sugawara M. Mukoyama, et al. 2001 Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis Am J Kidney Dis 38 4Suppl1 S134 S138 10.1053/ajkd.2001.27422 1:CAS:528:DC%2BD3MXnslKgtrg%3D 11576939
42. S. Mizuno T. Nakamura 2006 Molecular basis for HGF-mediated regression of renal fibrosis Nippon Rinsho 64 Suppl2 S312 S321